GlassScriptPhysician profile
Michael L Noel
NPI 1366447526
$4,299.50
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,023 · 2020: $999 · 2021: $1,229 · 2022: $27.66 · 2024: $21.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $530.17 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $530.10 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $351.55 | 2019-2021 | |
| Pfizer INC. | $332.42 | 2019-2021 | |
| Amarin Pharma, INC. | $310.74 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.29 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $223.30 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $201.94 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $164.64 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.22 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $152.90 | 2019-2021 | |
| Abbvie INC. | $127.53 | 2019-2022 | |
| Lilly USA, LLC | $126.14 | 2019 | |
| Astellas Pharma US INC | $85.63 | 2021 | |
| Glaxosmithkline, LLC. | $68.13 | 2019-2020 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $60.03 | 2021 | |
| Boston Scientific Corporation | $56.78 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $47.61 | 2019 | |
| Genentech USA, INC. | $45.81 | 2019-2021 | |
| Amgen INC. | $39.35 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $37.27 | 2021 | |
| Optinose US, INC. | $36.13 | 2019-2021 | |
| Dexcom, INC. | $31.36 | 2021 | |
| Biosense Webster, INC. | $31.33 | 2021 | |
| Ironwood Pharmaceuticals, INC | $30.82 | 2020 | |
| Sanofi Pasteur INC. | $28.38 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $22.30 | 2019 | |
| Abbott Laboratories | $21.27 | 2020 | |
| Axonics, INC. | $21.25 | 2024 | Axonics |
| Mylan Specialty L.P. | $18.98 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.62 | 2020 | |
| Bausch Health US, LLC | $18.53 | 2020 | |
| Redhill Biopharma INC. | $16.46 | 2020 | |
| Dynavax Technologies Corporation | $15.32 | 2019 | |
| Si-Bone, INC. | $14.36 | 2019 | |
| Currax Pharmaceuticals LLC | $14.01 | 2021 | |
| Neos Therapeutics, LP | $13.97 | 2020 | |
| Mayne Pharma Commercial LLC | $13.97 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.40 | 2021 | |
| Tersera Therapeutics LLC | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Noel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.